Zobrazeno 1 - 10
of 78
pro vyhledávání: '"G. R. D'Haens"'
Autor:
V Jairath, G Zou, G Radulescu, J Sigler, S C Mcfarlane, S Adsul, M Freire, L Peyrin-Biroulet, J F Colombel, G W Moran, S Sebastian, S Travis, S Vermeire, W J Sandborn, G R D’Haens, B G Feagan
Publikováno v:
Journal of Crohn's and Colitis. 17:i826-i829
Background Symptoms, endoscopy, histology, and biomarkers are used to evaluate disease activity and response to therapy in ulcerative colitis (UC). Histologic disease activity may persist in ~25% of patients with normal-appearing endoscopic mucosa, a
Autor:
M. A. Reijntjes, D. C. de Jong, S. Bartels, E. M. Wessels, E. K. Bocharewicz, R. Hompes, C. J. Buskens, G. R. d’Haens, M. Duijvestein, W. A. Bemelman
Publikováno v:
Techniques in Coloproctology, 27, 297-307
Techniques in Coloproctology, 27, 4, pp. 297-307
Techniques in coloproctology. Springer-Verlag Italia
Techniques in Coloproctology, 27, 4, pp. 297-307
Techniques in coloproctology. Springer-Verlag Italia
Background During ileal pouch-anal anastomosis (IPAA) surgery for ulcerative colitis (UC), rectal dissection can be performed via close rectal dissection (CRD) or in a total mesorectal excision plane (TME). Although CRD should protect autonomic nerve
Autor:
L Peyrin-Biroulet, J F Colombel, E Louis, M Ferrante, S Motoya, R Panaccione, J Torres, R C Ungaro, K Kligys, J Kalabic, J Zambrano, Y Zhang, G R D’Haens
Publikováno v:
Journal of Crohn's and Colitis. 16:i045-i048
Background An association between shorter disease duration and improved clinical efficacy has been shown in post hoc analyses of clinical trial data with biological therapies in Crohn’s disease (CD). The efficacy and safety of risankizumab (RZB) as
Autor:
V Jairath, G Zou, Z Wang, S Adsul, J F Colombel, G R D’Haens, M Freire, G W Moran, L Peyrin-Biroulet, W J Sandborn, S Sebastian, S Travis, S Vermeire, G Radulescu, J Sigler, S Mcfarlane, N Arya, M Beaton, P Bossuyt, D Green, W Harlan III, M Horynski, M Klopocka, R Petroniene, M S Silverberg, L Wolanski, B G Feagan
Publikováno v:
Journal of Crohn's and Colitis. 17:i716-i717
Background The optimal treatment target for ulcerative colitis (UC) is uncertain. The VERDICT trial in moderate to severe UC aims to determine if a treatment target of corticosteroid (CS)-free symptomatic + endoscopic + histologic remission is superi
Publikováno v:
Journal of Crohn's and Colitis. 17:i602-i603
Background Increasing evidence suggests appendectomy as a potential experimental therapy for ulcerative colitis (UC). A prospective cohort study of laparoscopic appendectomy for treatment of therapy refractory UC showed a clinical response in nearly
Autor:
R Sedano, C Ma, M Hogan, M S Silverberg, G Zou, G R D’Haens, J Rémillard, S C Mcfarlane, B Bojic, B Bressler, G Rosenfeld, R M Feakins, R Kirsch, A Marchal, M A Samaan, R Panaccione, A Hart, B E Sands, S Travis, B G Feagan, V Jairath
Publikováno v:
Journal of Crohn's and Colitis. 17:i416-i417
Background Several instruments have been used in clinical trials of pouchitis to define eligibility criteria and outcome measures but have not been formally validated. A need remains for a validated pouchitis instrument that is suitable for use in no
Publikováno v:
Journal of Crohn's and Colitis. 17:i803-i804
Background Immunogenicity to anti-TNF agents is associated with loss of response in inflammatory bowel disease (IBD). However, the efficacy of different strategies to restore favourable pharmacokinetics and/or clinical response upon the detection of
Autor:
M Reijntjes, M Pruijt, E Visser, F de Voogd, G R d'Haens, A Mookhoek, K B Gecse, C J Buskens, W A Bemelman
Publikováno v:
Journal of Crohn's and Colitis. 17:i454-i455
Background Increasing evidence suggests appendectomy as potential alternative treatment in patients with ulcerative colitis (UC), especially in those with histological appendiceal inflammation (AI). Intestinal ultrasound (IUS) is a non-invasive diagn
Autor:
L Peyrin-Biroulet, S Vermeire, G R D’Haens, J Panés, A Dignass, F Magro, M Le Bars, M Lahaye, M Nazar, L Ni, I Bravatà, F Lavie, M Daperno, M Lukáš, A Armuzzi, M Löwenberg, D R Gaya, S Danese
Publikováno v:
Journal of Crohn's and Colitis. 16:i132-i134
Background STARDUST is a phase 3b randomized trial comparing two therapeutic strategies with ustekinumab (UST) in patients (pts) with Crohn’s disease (CD): treat-to-target (T2T) using early endoscopic assessment vs standard of care (SoC). Results f
Autor:
W Reinisch, J F Colombel, G R D’Haens, J Rimola, A DeHaas-Amatsaleh, M McKevitt, X Ren, A Serone, D A Schwartz, K B Gecse
Publikováno v:
Journal of Crohn's and Colitis. 16:i019-i021
Background Treatment of perianal fistulizing Crohn’s disease (PFCD) is a major unmet need. Filgotinib (FIL) is a once-daily, oral, preferential Janus kinase 1 inhibitor in development for the treatment of inflammatory bowel diseases. The efficacy a